Key result
R-CHOP therapy stabilized the clinical state of a 62-year-old male with primary cardiac lymphoma presenting with syncope and cardiac tamponade at 3 months follow-up.
Why the study?
Primary cardiac lymphoma is extremely rare with poor prognosis, typically presenting with heart failure, pericardial effusion, tamponade, or arrhythmias.
Case Report (n=1)
Highlights a rare case of primary cardiac lymphoma presenting with syncope and cardiac tamponade, successfully stabilized with R-CHOP therapy after surgical failure.
Answers are grounded in this paper and cite their sources.
May support R-CHOP in rare primary cardiac lymphoma with tamponade; hypothesis-generating from single case report.
Primary cardiac lymphoma (PCL) is among the rarest heart neoplasms. Its estimated incidence is about 1%-2% among primary cardiac tumor and 0.5% of extranodal lymphoma. It usually causes heart failure, pericardial effusion, tamponade, and arrhythmias. Prognosis is poor; treatment is combined medical and surgical. We described the case of a 62-year-old male with PLC that presented with syncope and cardiac tamponade, submitted to R-CHOP therapy because of failure of surgery. Clinical state is stable 3 months after diagnosis and first chemotherapy cycle.
No takes yet. Share an insight, caveat, or question.
Serra et al. (2021) conducted a case report in Primary cardiac lymphoma (n=1). R-CHOP therapy was evaluated on Clinical state. R-CHOP therapy stabilized the clinical state of a 62-year-old male with primary cardiac lymphoma presenting with syncope and cardiac tamponade at 3 months follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: